severe oligospermia or azoospermia
Conditions
Interventions
1:75IU uFSH (Livzon Pharm Group Inc., China) being injected into patients every 3 days for 6 months
2:75IU uFSH (Livzon Pharm Group Inc., China) being injected into patients every 3 days for 6 months
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
Male
Age
20 Years to 35 Years
Inclusion criteria
Inclusion criteria: Male subjects aged 20~35; They accorded with diagnostic criteria of severe oligospermia or azoospermia; They had'nt been treated with drug which could improve sperm count and quality one month before observation, otherwise, they should have a elution for 1 month before the study.
Exclusion criteria
Exclusion criteria: Gram-positive bacteria, Chlamydia trachomatis, Ureaplasmaurealyticum, or mycoplasma hominis were detected in their semen; Subjects addicted to drug, tobacco, or alcohol; Subjects had heat, chemicals, radioactive material, or toxic contact history within a year; Subjects were under treatment of gonadotropin,anabolic steroid, chemotherapeutic drugs, or nonsteroidal anti-inflammatory drugs; Subjects combined with cardiovascular, liver, kidney, or hematopoietic system severe primary disease, or mental disease; Subjects were allergic or on uFSH allergy, or under the treatment of other drugs for infertility; Subjects did not meet the inclusion criteria, did not according to the prescribed medication, were unable to judge the efficacy, had incomplete information, or affected the efficacy or safety judgment; Subjects were IHH patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hormonal level in vivo;testicular volume;sperm density;sperm motility of level (a+b);sperm of level a;semen volume; | — |
Countries
China
Contacts
Public ContactJiang Hui
Outcome results
None listed